İlaçlarla ilişkili çene osteonekrozu (MRONJ)’nda güncel tedavi yaklaşımları. Literatürün gözden geçirilmesi

Year 2022, Volume: 32 Issue: 4 - 2022, 32:4, 305 - 314, 21.10.2022

Buse Korkut Esengül Şen Yunus Balel1

https://doi.org/10.17567/ataunidfd.822569

Abstract

Bifosfonatların, antirezorptif ilaçların ve antianjiojenik ilaçların etkisiyle çenelerde görülen osteonekrozlar tıp ve özellikle diş hekimliği alanında ciddi sorunlara yol açmaktadır. Bu ilaçları kullanan hastalarda kemik açığa çıkabilir veya mukoza bütünlüğü sağlam kalıp etkilenen kemik dokusu sağlıklı mukozanın altında olabilir. Bu derlemenin amacı MRONJ hakkında genel bilgi sağlamak; uygulanan güncel tedavi yöntemlerinin derlemesi ve daha yenilikçi bir tedavi yöntemi olan kök hücre tedavisinin incelenmesidir. Bu kapsamda yapılan literatür incelemesi sonucu farklı yöntemler yayında özetlenerek okuyuculara sunulmuştur.

Anahtar Kelimeler: MRONJ, kök hücre, tedavi

Keywords

MRONJ, kök hücre, tedavi

References

• 1. Gómez Font R, Martínez García ML, Olmos Martínez JM. Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update. Med Oral Patol Oral Cir Bucal. 2008;13(5):E318-24.
• 2. Erdem NF, Gümüşer Z. Bifosfonat Kullanımına Bağlı Çene Kemiklerinde Görülen Osteonekroz Vakalarının Medikal ve Cerrahi Tedavileri Sonrası Uzun Dönem Takipleri. Atatürk Üniversitesi Diş Hekim Fakültesi Derg. 2020:1-1.
• 3. Marx RE, Cillo JEJ, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2007;65(12):2397-2410.
• 4. Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens). 2009;8(2):96-110.
• 5. Fleisch HA, Russell RG, Bisaz S, Mühlbauer RC, Williams DA. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest. 1970;1(1):12-18.
• 6. Russell RG, Rogers MJ, Frith JC, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J bone Miner Res Off J Am Soc Bone Miner Res. 1999;14 Suppl 2:53-65.
• 7. Smith R, Russell RG, Bishop M. Diphosphonates and Page’s disease of bone. Lancet (London, England). 1971;1(7706):945-947.
• 8. Russell RGG. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2-19.
• 9. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(17):3719-3736.
• 10. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(6):1378-1391. 11. Diel IJ, Bergner R, Grötz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol. 2007;5(10):475-482.
• 12. Honig S, Chang G. Osteoporosis: an update. Bull NYU Hosp Jt Dis. 2012;70(3):140-144.
• 13. Orozco C, Maalouf NM. Safety of bisphosphonates. Rheum Dis Clin North Am. 2012;38(4):681-705.
• 14. Marx RE. Osteoradionecrosis: a new concept of its pathophysiology. J oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 1983;41(5):283-288.
• 15. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2009;67(5 Suppl):2-12.
• 16. Sarin J, DeRossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis. 2008;14(3):277-285.
• 17. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2014;72(10):1938-1956.
• 18. Otto S, Schreyer C, Hafner S, et al. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. J cranio-maxillo-facial Surg Off Publ Eur Assoc Cranio-Maxillo-Facial Surg. 2012;40(4):303-309.
• 19. Longo F, Guida A, Aversa C, et al. Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature. Int J Dent. 2014;2014:298945.
• 20. Karasneh JA, Al-Eryani K, Clark GT, Sedghizadeh PP. Modified protocol including topical minocycline in orabase to manage medication-related osteonecrosis of the jaw cases. J oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2016;45(9):718-720.
• 21. Matsumoto A, Sasaki M, Schmelzeisen R, Oyama Y, Mori Y, Voss PJ. Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab. Clin Oral Investig. 2017;21(1):127-134.
• 22. Lorenzo S Di, Trapassi A, Corradino B, Cordova A. Histology of the Oral Mucosa in Patients With BRONJ at III Stage: A Microscopic Study Proves the Unsuitability of Local Mucosal Flaps. J Clin Med Res. 2013;5(1):22-25.
• 23. Pribaz J, Stephens W, Crespo L, Gifford G. A new intraoral flap: facial artery musculomucosal (FAMM) flap. Plast Reconstr Surg. 1992;90(3):421-429.
• 24. Stofman GM. Facial artery musculomucosal flap. Plast Reconstr Surg. 1993;91(6):1170-1171.
• 25. Mast G, Otto S, Mücke T, et al. Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw. J cranio-maxillo-facial Surg Off Publ Eur Assoc Cranio-Maxillo-Facial Surg. 2012;40(7):568-571.
• 26. Gallego L, Junquera L, Pelaz A, Hernando J, Megías J. The use of pedicled buccal fat pad combined with sequestrectomy in bisphosphonate-related osteonecrosis of the maxilla. Med Oral Patol Oral Cir Bucal. 2012;17(2):e236-41.
• 27. Dean A, Alamillos F, García-López A, Sánchez J, Peñalba M. The buccal fat pad flap in oral reconstruction. Head Neck. 2001;23(5):383-388.
• 28. Nabil S, Ramli R. The use of buccal fat pad flap in the treatment of osteoradionecrosis. Int J Oral Maxillofac Surg. 2013;42(4):548-549.
• 29. Magalhães IA, Forte CPF, Viana TSA, et al. Photobiomodulation and antimicrobial photodynamic therapy as adjunct in the treatment and prevention of osteoradionecrosis of the jaws: A case report. Photodiagnosis Photodyn Ther. 2020;31:101959.
• 30. Vescovi P, Merigo E, Meleti M, Manfredi M. Bisphosphonate-associated osteonecrosis (BON) of the jaws: a possible treatment? J oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2006;64(9):1460-1462.
• 31. Göl EB, Özkan N, Bereket C, Önger ME. Extracorporeal Shock-Wave Therapy or Low-Level Laser Therapy: Which is More Effective in Bone Healing in Bisphosphonate Treatment? J Craniofac Surg. 2020;31(7):2043-2048.
• 32. Posten W, Wrone DA, Dover JS, Arndt KA, Silapunt S, Alam M. Low-level laser therapy for wound healing: mechanism and efficacy. Dermatologic Surg Off Publ Am Soc Dermatologic Surg [et al]. 2005;31(3):334-340.
• 33. Tam SY, Tam VCW, Ramkumar S, Khaw ML, Law HKW, Lee SWY. Review on the Cellular Mechanisms of Low-Level Laser Therapy Use in Oncology. Front Oncol. 2020;10:1255.
• 34. Fischlechner R, Kofler B, Schartinger VH, Dudas J, Riechelmann H. Does low-level laser therapy affect the survival of patients with head and neck cancer? Lasers Med Sci. June 2020.
• 35. Guzzardella GA, Fini M, Torricelli P, Giavaresi G, Giardino R. Laser stimulation on bone defect healing: an in vitro study. Lasers Med Sci. 2002;17(3):216-220.
• 36. Khadra M, Kasem N, Haanaes HR, Ellingsen JE, Lyngstadaas SP. Enhancement of bone formation in rat calvarial bone defects using low-level laser therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97(6):693-700.
• 37. Medrado ARAP, Pugliese LS, Reis SRA, Andrade ZA. Influence of low level laser therapy on wound healing and its biological action upon myofibroblasts. Lasers Surg Med. 2003;32(3):239-244.
• 38. Garavello-Freitas I, Baranauskas V, Joazeiro PP, Padovani CR, Dal Pai-Silva M, da Cruz-Höfling MA. Low-power laser irradiation improves histomorphometrical parameters and bone matrix organization during tibia wound healing in rats. J Photochem Photobiol B. 2003;70(2):81-89.
• 39. Vescovi P, Nammour S. Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review. Minerva Stomatol. 2010;59(4):181-203,204-213.
• 40. Scoletta M, Arduino PG, Reggio L, Dalmasso P, Mozzati M. Effect of low-level laser irradiation on bisphosphonate-induced osteonecrosis of the jaws: preliminary results of a prospective study. Photomed Laser Surg. 2010;28(2):179-184.
• 41. Romeo U, Galanakis A, Marias C, et al. Observation of pain control in patients with bisphosphonate-induced osteonecrosis using low level laser therapy: preliminary results. Photomed Laser Surg. 2011;29(7):447-452.
• 42. Ristow O, Rückschloß T, Moratin J, et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Dis. Published online July 2020.
• 43. Vescovi P, Meleti M, Merigo E, et al. Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd:YAG low-level laser therapy. Med Oral Patol Oral Cir Bucal. 2013;18(4):e680-5.
• 44. Dieleman FJ, Meijer GJ, Merkx MAW. Does hyperbaric oxygen therapy play a role in the management of osteoradionecrosis? A survey of Dutch oral and maxillofacial surgeons. Int J Oral Maxillofac Surg. Published online July 2020.
• 45. Chen Y-C, Sheu J-J, Chiang JY, et al. Circulatory Rejuvenated EPCs Derived from PAOD Patients Treated by CD34(+) Cells and Hyperbaric Oxygen Therapy Salvaged the Nude Mouse Limb against Critical Ischemia. Int J Mol Sci. 2020;21(21).
• 46. Boykin JVJ, Baylis C. Hyperbaric oxygen therapy mediates increased nitric oxide production associated with wound healing: a preliminary study. Adv Skin Wound Care. 2007;20(7):382-388.
• 47. Asano T, Kaneko E, Shinozaki S, et al. Hyperbaric oxygen induces basic fibroblast growth factor and hepatocyte growth factor expression, and enhances blood perfusion and muscle regeneration in mouse ischemic hind limbs. Circ J. 2007;71(3):405-411.
• 48. Niu Y-B, Yang Y-Y, Xiao X, et al. Quercetin prevents bone loss in hindlimb suspension mice via stanniocalcin 1-mediated inhibition of osteoclastogenesis. Acta Pharmacol Sin. 2020;41(11):1476-1486.
• 49. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2007;65(7):1321-1327.
• 50. Sandhu S, Salous MH, Sankar V, Margalit DN, Villa A. Osteonecrosis of the jaw and dental extractions: a single-center experience. Oral Surg Oral Med Oral Pathol Oral Radiol. Published online July 2020.
• 51. Mehraban F, Seyedarabi A, Seraj Z, et al. Molecular insights into the effect of ozone on human hemoglobin in autohemotherapy: Highlighting the importance of the presence of blood antioxidants during ozonation. Int J Biol Macromol. 2018;119:1276-1285.
• 52. Agrillo A, Petrucci MT, Tedaldi M, et al. New therapeutic protocol in the treatment of avascular necrosis of the jaws. J Craniofac Surg. 2006;17(6):1080-1083.
• 53. Ripamonti CI, Cislaghi E, Mariani L, Maniezzo M. Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study. Oral Oncol. 2011;47(3):185-190.
• 54. Amaral Valladão CAJ, Freitas Monteiro M, Joly JC. Guided bone regeneration in staged vertical and horizontal bone augmentation using platelet-rich fibrin associated with bone grafts: a retrospective clinical study. Int J Implant Dent. 2020;6(1):72.
• 55. Tenore G, Zimbalatti A, Rocchetti F, et al. Management of Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Leukocyte- and Platelet-Rich Fibrin (L-PRF) and Photobiomodulation: A Retrospective Study. J Clin Med. 2020;9(11).
• 56. Zelinka J, Blahak J, Perina V, Pacasova R, Treglerova J, Bulik O. The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study. Biomed Pap Med Fac Univ Palacky, Olomouc, Czechoslov. Published online June 2020.
• 57. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27(3):158-167.
• 58. Dincă O, Zurac S, Stăniceanu F, et al. Clinical and histopathological studies using fibrin-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw. Rom J Morphol Embryol = Rev Roum Morphol Embryol. 2014;55(3):961-964.
• 59. Cano-Durán JA, Peña-Cardelles J-F, Ortega-Concepción D, Paredes-Rodríguez VM, García-Riart M, López-Quiles J. The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). J Clin Exp Dent. 2017;9(8):e1051-e1059.
• 60. Park J-H, Kim J-W, Kim S-J. Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw? J oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2017;75(6):1176-1184.
• 61. Kim J-W, Kim S-J, Kim M-R. Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study. Br J Oral Maxillofac Surg. 2014;52(9):854-859.
• 62. Lesclous P, Grabar S, Abi Najm S, et al. Relevance of surgical management of patients affected by bisphosphonate-associated osteonecrosis of the jaws. A prospective clinical and radiological study. Clin Oral Investig. 2014;18(2):391-399.
• 63. Rupel K, Ottaviani G, Gobbo M, et al. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol. 2014;50(11):1049-1057.
• 64. Bouland C, Meuleman N, Widelec J, et al. Case reports of medication-related osteonecrosis of the jaw (MRONJ) treated with uncultured stromal vascular fraction and L-PRF. J Stomatol oral Maxillofac Surg. Published online June 2020.
• 65. Fortier LA. Stem cells: classifications, controversies, and clinical applications. Vet Surg. 2005;34(5):415-423.
• 66. Bluteau G, Luder HU, De Bari C, Mitsiadis TA. Stem cells for tooth engineering. Eur Cell Mater. 2008;16:1-9.
• 67. Zhao S, Liu Y, Pu Z. Bone marrow mesenchymal stem cell-derived exosomes attenuate D-GaIN/LPS-induced hepatocyte apoptosis by activating autophagy in vitro. Drug Des Devel Ther. 2019;13:2887-2897.
• 68. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7(2):211-228.
• 69. Huang GT-J, Gronthos S, Shi S. Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine. J Dent Res. 2009;88(9):792-806.
• 70. Miura M, Gronthos S, Zhao M, et al. SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci U S A. 2003;100(10):5807-5812.
• 71. Seo B-M, Miura M, Gronthos S, et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet (London, England). 2004;364(9429):149-155.
• 72. Sonoyama W, Liu Y, Yamaza T, et al. Characterization of the apical papilla and its residing stem cells from human immature permanent teeth: a pilot study. J Endod. 2008;34(2):166-171.
• 73. Morsczeck C, Götz W, Schierholz J, et al. Isolation of precursor cells (PCs) from human dental follicle of wisdom teeth. Matrix Biol. 2005;24(2):155-165.
• 74. Graziano A, d’Aquino R, Laino G, Papaccio G. Dental pulp stem cells: a promising tool for bone regeneration. Stem Cell Rev. 2008;4(1):21-26.
• 75. Zhang Q, Atsuta I, Liu S, et al. IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws. Clin cancer Res an Off J Am Assoc Cancer Res. 2013;19(12):3176-3188.
• 76. Ding L, Han D-M, Zheng X-L, et al. A study of human leukocyte antigen-haploidentical hematopoietic stem cells transplantation combined with allogenic mesenchymal stem cell infusion for treatment of severe aplastic anemia in pediatric and adolescent patients. Stem Cells Transl Med. Published online September 2020.
• 77. Tahmasebi F, Pasbakhsh P, Barati S, Madadi S, Kashani IR. The effect of microglial ablation and mesenchymal stem cell transplantation on a cuprizone-induced demyelination model. J Cell Physiol. Published online September 2020.
• 78. Gallo G, Tiesi V, Fulginiti S, De Paola G, Vescio G, Sammarco G. Mesenchymal Stromal Cell Therapy in the Management of Perianal Fistulas in Crohn’s Disease: An Up-To-Date Review. Medicina (Kaunas). 2020;56(11).
• 79. Matsuura Y, Atsuta I, Ayukawa Y, et al. Therapeutic interactions between mesenchymal stem cells for healing medication-related osteonecrosis of the jaw. Stem Cell Res Ther. 2016;7(1):119.
• 80. Kaibuchi N, Iwata T, Yamato M, Okano T, Ando T. Multipotent mesenchymal stromal cell sheet therapy for bisphosphonate-related osteonecrosis of the jaw in a rat model. Acta Biomater. 2016;42:400-410.
• 81. Rodríguez-Lozano FJ, Oñate-Sánchez R, Gonzálvez-García M, et al. Allogeneic Bone Marrow Mesenchymal Stem Cell Transplantation in Tooth Extractions Sites Ameliorates the Incidence of Osteonecrotic Jaw-Like Lesions in Zoledronic Acid-Treated Rats. J Clin Med. 2020;9(6).
• 82. Friedenstein AJ, Deriglasova UF, Kulagina NN, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;2(2):83-92.
• 83. Veyrat-Masson R, Boiret-Dupré N, Rapatel C, et al. Mesenchymal content of fresh bone marrow: a proposed quality control method for cell therapy. Br J Haematol. 2007;139(2):312-320.
• 84. Poltavtseva RA, Nikonova YA, Selezneva II, et al. Mesenchymal stem cells from human dental pulp: isolation, characteristics, and potencies of targeted differentiation. Bull Exp Biol Med. 2014;158(1):164-169.
• 85. Bernardo ME, Avanzini MA, Ciccocioppo R, et al. Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn’s disease. Cytotherapy. 2009;11(7):825-836.
• 86. Hou R, Liu R, Niu X, et al. Biological characteristics and gene expression pattern of bone marrow mesenchymal stem cells in patients with psoriasis. Exp Dermatol. 2014;23(7):521-523.
• 87. Siegel G, Kluba T, Hermanutz-Klein U, Bieback K, Northoff H, Schäfer R. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med. 2013;11:146.
• 88. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001;98(18):10344-10349.
• 89. Lonergan T, Brenner C, Bavister B. Differentiation-related changes in mitochondrial properties as indicators of stem cell competence. J Cell Physiol. 2006;208(1):149-153.
• 90. Mandal S, Lindgren AG, Srivastava AS, Clark AT, Banerjee U. Mitochondrial function controls proliferation and early differentiation potential of embryonic stem cells. Stem Cells. 2011;29(3):486-495.
• 91. Tamari T, Elimelech R, Cohen G, et al. Endothelial Progenitor Cells inhibit jaw osteonecrosis in a rat model: A major adverse effect of bisphosphonate therapy. Sci Rep. 2019;9(1):18896.